These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30990907)

  • 21. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate.
    Lee BA; Lee MS; Maltry AC; Hou JH
    Cornea; 2021 Sep; 40(9):1197-1200. PubMed ID: 33201054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.
    Gibiansky L; Passey C; Voellinger J; Gunawan R; Hanley WD; Gupta M; Winter H
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1358-1370. PubMed ID: 35932175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
    Rathi C; Collins J; Struemper H; Opalinska J; Jewell RC; Ferron-Brady G
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):851-863. PubMed ID: 34076364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.
    Porath KA; Regan MS; Griffith JI; Jain S; Stopka SA; Burgenske DM; Bakken KK; Carlson BL; Decker PA; Vaubel RA; Dragojevic S; Mladek AC; Connors MA; Hu Z; He L; Kitange GJ; Gupta SK; Feldsien TM; Lefebvre DR; Agar NYR; Eckel-Passow JE; Reilly EB; Elmquist WF; Sarkaria JN
    Neurooncol Adv; 2022; 4(1):vdac130. PubMed ID: 36071925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
    Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
    Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
    Li H; Han TH; Hunder NN; Jang G; Zhao B
    J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
    Gan HK; Parakh S; Lassman AB; Seow A; Lau E; Lee ST; Ameratunga M; Perchyonok Y; Cao D; Burvenich IJG; O'Keefe GJ; Rigopoulos A; Gomez E; Maag D; Scott AM
    Neurooncol Adv; 2021; 3(1):vdab102. PubMed ID: 34549181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Belantamab Mafodotin: First Approval.
    Markham A
    Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
    Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
    AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
    Pouzin C; Gibiansky L; Fagniez N; Chadjaa M; Tod M; Nguyen L
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):381-394. PubMed ID: 35166967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF
    Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
    Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
    Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
    Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
    Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
    Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
    Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC.
    Figueroa I; Leipold D; Leong S; Zheng B; Triguero-Carrasco M; Fourie-O'Donohue A; Kozak KR; Xu K; Schutten M; Wang H; Polson AG; Kamath AV
    MAbs; 2018 Jul; 10(5):738-750. PubMed ID: 29757698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates.
    Zhang D; Yu SF; Ma Y; Xu K; Dragovich PS; Pillow TH; Liu L; Del Rosario G; He J; Pei Z; Sadowsky JD; Erickson HK; Hop CE; Khojasteh SC
    Drug Metab Dispos; 2016 Sep; 44(9):1517-23. PubMed ID: 27417182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
    Kim SB; Meric-Bernstam F; Kalyan A; Babich A; Liu R; Tanigawa T; Sommer A; Osada M; Reetz F; Laurent D; Wittemer-Rump S; Berlin J
    Target Oncol; 2019 Oct; 14(5):591-601. PubMed ID: 31502117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.
    Wada R; Erickson HK; Lewis Phillips GD; Provenzano CA; Leipold DD; Mai E; Johnson H; Tibbitts J
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):969-80. PubMed ID: 25186956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.